Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation

W. B. Rybka, P. A. Fontes, A. S. Rao, A. Winkelstein, Camillo Ricordi, E. D. Ball, T. E. Starzl

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

While cadaveric vertebral bodies (VB) have long been proposed as a suitable source of bone marrow (BM) for transplantation (BMT), they have rarely been used for this purpose. We have infused VB BM immediately following whole organ (WO) transplantation to augment donor cell chimerism. We quantified the hematopoietic progenitor cell (HPC) content of VB BM as well as BM obtained from the iliac crests (IC) of normal allogeneic donors (ALLO) and from patients with malignancy undergoing autologous marrow harvest (AUTO). Patients undergoing WO/BM transplantation also had AUTO BM harvested in the event that subsequent lymphohematopoietic reconstitution was required. Twenty-four VB BM, 24 IC BM-ALLO, 31 IC AUTO, and 24 IC WO-AUTO were harvested. VB BM was tested 12 to 72 hr after procurement and infused after completion of WO grafting. IC BM was tested and then used or cryopreserved immediately. HPC were quantified by clonal assay measuring CFU-GM, BFU-E, and CFU-GEMM, and by flow cytometry for CD34+ progenitor cells. On an average, 9 VB were processed during each harvest, and despite an extended processing time the number of viable nucleated cells obtained was significantly higher than that from IC. Furthermore, by HPC content, VB BM was equivalent to IC BM, which is routinely used for BMT. We conclude that VB BM is a clinically valuable source of BM for allogeneic transplantation.

Original languageEnglish
Pages (from-to)871-874
Number of pages4
JournalTransplantation
Volume59
Issue number6
StatePublished - Jan 1 1995

Fingerprint

Hematopoietic Stem Cells
Bone Marrow Transplantation
Bone Marrow
Tissue Donors
Organ Transplantation
Myeloid Progenitor Cells
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Chimerism
Homologous Transplantation
Flow Cytometry
Stem Cells
Transplantation
Bone and Bones

ASJC Scopus subject areas

  • Immunology
  • Transplantation

Cite this

Rybka, W. B., Fontes, P. A., Rao, A. S., Winkelstein, A., Ricordi, C., Ball, E. D., & Starzl, T. E. (1995). Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation. Transplantation, 59(6), 871-874.

Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation. / Rybka, W. B.; Fontes, P. A.; Rao, A. S.; Winkelstein, A.; Ricordi, Camillo; Ball, E. D.; Starzl, T. E.

In: Transplantation, Vol. 59, No. 6, 01.01.1995, p. 871-874.

Research output: Contribution to journalArticle

Rybka, WB, Fontes, PA, Rao, AS, Winkelstein, A, Ricordi, C, Ball, ED & Starzl, TE 1995, 'Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation', Transplantation, vol. 59, no. 6, pp. 871-874.
Rybka, W. B. ; Fontes, P. A. ; Rao, A. S. ; Winkelstein, A. ; Ricordi, Camillo ; Ball, E. D. ; Starzl, T. E. / Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation. In: Transplantation. 1995 ; Vol. 59, No. 6. pp. 871-874.
@article{55252956f4b0479c9b63fbcefd21187a,
title = "Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation",
abstract = "While cadaveric vertebral bodies (VB) have long been proposed as a suitable source of bone marrow (BM) for transplantation (BMT), they have rarely been used for this purpose. We have infused VB BM immediately following whole organ (WO) transplantation to augment donor cell chimerism. We quantified the hematopoietic progenitor cell (HPC) content of VB BM as well as BM obtained from the iliac crests (IC) of normal allogeneic donors (ALLO) and from patients with malignancy undergoing autologous marrow harvest (AUTO). Patients undergoing WO/BM transplantation also had AUTO BM harvested in the event that subsequent lymphohematopoietic reconstitution was required. Twenty-four VB BM, 24 IC BM-ALLO, 31 IC AUTO, and 24 IC WO-AUTO were harvested. VB BM was tested 12 to 72 hr after procurement and infused after completion of WO grafting. IC BM was tested and then used or cryopreserved immediately. HPC were quantified by clonal assay measuring CFU-GM, BFU-E, and CFU-GEMM, and by flow cytometry for CD34+ progenitor cells. On an average, 9 VB were processed during each harvest, and despite an extended processing time the number of viable nucleated cells obtained was significantly higher than that from IC. Furthermore, by HPC content, VB BM was equivalent to IC BM, which is routinely used for BMT. We conclude that VB BM is a clinically valuable source of BM for allogeneic transplantation.",
author = "Rybka, {W. B.} and Fontes, {P. A.} and Rao, {A. S.} and A. Winkelstein and Camillo Ricordi and Ball, {E. D.} and Starzl, {T. E.}",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "59",
pages = "871--874",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Hematopoietic progenitor cell content of vertebral body marrow used for combined solid organ and bone marrow transplantation

AU - Rybka, W. B.

AU - Fontes, P. A.

AU - Rao, A. S.

AU - Winkelstein, A.

AU - Ricordi, Camillo

AU - Ball, E. D.

AU - Starzl, T. E.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - While cadaveric vertebral bodies (VB) have long been proposed as a suitable source of bone marrow (BM) for transplantation (BMT), they have rarely been used for this purpose. We have infused VB BM immediately following whole organ (WO) transplantation to augment donor cell chimerism. We quantified the hematopoietic progenitor cell (HPC) content of VB BM as well as BM obtained from the iliac crests (IC) of normal allogeneic donors (ALLO) and from patients with malignancy undergoing autologous marrow harvest (AUTO). Patients undergoing WO/BM transplantation also had AUTO BM harvested in the event that subsequent lymphohematopoietic reconstitution was required. Twenty-four VB BM, 24 IC BM-ALLO, 31 IC AUTO, and 24 IC WO-AUTO were harvested. VB BM was tested 12 to 72 hr after procurement and infused after completion of WO grafting. IC BM was tested and then used or cryopreserved immediately. HPC were quantified by clonal assay measuring CFU-GM, BFU-E, and CFU-GEMM, and by flow cytometry for CD34+ progenitor cells. On an average, 9 VB were processed during each harvest, and despite an extended processing time the number of viable nucleated cells obtained was significantly higher than that from IC. Furthermore, by HPC content, VB BM was equivalent to IC BM, which is routinely used for BMT. We conclude that VB BM is a clinically valuable source of BM for allogeneic transplantation.

AB - While cadaveric vertebral bodies (VB) have long been proposed as a suitable source of bone marrow (BM) for transplantation (BMT), they have rarely been used for this purpose. We have infused VB BM immediately following whole organ (WO) transplantation to augment donor cell chimerism. We quantified the hematopoietic progenitor cell (HPC) content of VB BM as well as BM obtained from the iliac crests (IC) of normal allogeneic donors (ALLO) and from patients with malignancy undergoing autologous marrow harvest (AUTO). Patients undergoing WO/BM transplantation also had AUTO BM harvested in the event that subsequent lymphohematopoietic reconstitution was required. Twenty-four VB BM, 24 IC BM-ALLO, 31 IC AUTO, and 24 IC WO-AUTO were harvested. VB BM was tested 12 to 72 hr after procurement and infused after completion of WO grafting. IC BM was tested and then used or cryopreserved immediately. HPC were quantified by clonal assay measuring CFU-GM, BFU-E, and CFU-GEMM, and by flow cytometry for CD34+ progenitor cells. On an average, 9 VB were processed during each harvest, and despite an extended processing time the number of viable nucleated cells obtained was significantly higher than that from IC. Furthermore, by HPC content, VB BM was equivalent to IC BM, which is routinely used for BMT. We conclude that VB BM is a clinically valuable source of BM for allogeneic transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0028967592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028967592&partnerID=8YFLogxK

M3 - Article

C2 - 7701582

AN - SCOPUS:0028967592

VL - 59

SP - 871

EP - 874

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -